123 related articles for article (PubMed ID: 27746118)
1. Molecular features of doxorubicin-resistance development in colorectal cancer CX-1 cell line.
Kubiliūtė R; Šulskytė I; Daniūnaitė K; Daugelavičius R; Jarmalaitė S
Medicina (Kaunas); 2016; 52(5):298-306. PubMed ID: 27746118
[TBL] [Abstract][Full Text] [Related]
2. Nongenotoxic ABCB1 activator tetraphenylphosphonium can contribute to doxorubicin resistance in MX-1 breast cancer cell line.
Kubiliute R; Januskeviciene I; Urbanaviciute R; Daniunaite K; Drobniene M; Ostapenko V; Daugelavicius R; Jarmalaite S
Sci Rep; 2021 Mar; 11(1):6556. PubMed ID: 33753859
[TBL] [Abstract][Full Text] [Related]
3. Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells.
Li J; Liu H; Yu J; Yu H
Mol Med Rep; 2015 Jul; 12(1):192-8. PubMed ID: 25684678
[TBL] [Abstract][Full Text] [Related]
4. Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells.
Pang E; Hu Y; Chan KY; Lai PB; Squire JA; Macgregor PF; Beheshti B; Albert M; Leung TW; Wong N
Lab Invest; 2005 May; 85(5):664-74. PubMed ID: 15765123
[TBL] [Abstract][Full Text] [Related]
5. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
6. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line.
Rajkumar T; Yamuna M
Anticancer Drugs; 2008 Mar; 19(3):257-65. PubMed ID: 18510171
[TBL] [Abstract][Full Text] [Related]
7. Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1).
Yan X; Zhao J; Zhang R
Cancer Chemother Pharmacol; 2017 Aug; 80(2):395-403. PubMed ID: 28667355
[TBL] [Abstract][Full Text] [Related]
8. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription.
Ye P; Xing H; Lou F; Wang K; Pan Q; Zhou X; Gong L; Li D
Cancer Chemother Pharmacol; 2016 Mar; 77(3):613-21. PubMed ID: 26846508
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of doxorubicin resistance in human leukemia HL-60 cells is reproducibly associated with 7q21 chromosomal anomalies.
Ganapathi R; Hoeltge G; Casey G; Grabowski D; Neelon R; Ford J
Cancer Genet Cytogenet; 1996 Feb; 86(2):116-9. PubMed ID: 8603335
[TBL] [Abstract][Full Text] [Related]
11. The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update.
Torki Z; Ghavi D; Hashemi S; Rahmati Y; Rahmanpour D; Pornour M; Alivand MR
Cancer Chemother Pharmacol; 2021 Nov; 88(5):771-793. PubMed ID: 34510251
[TBL] [Abstract][Full Text] [Related]
12. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
13. Cx32 reverses epithelial-mesenchymal transition in doxorubicin-resistant hepatocellular carcinoma.
Yu M; Han G; Qi B; Wu X
Oncol Rep; 2017 Apr; 37(4):2121-2128. PubMed ID: 28260043
[TBL] [Abstract][Full Text] [Related]
14. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
Tsou SH; Chen TM; Hsiao HT; Chen YH
PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866
[TBL] [Abstract][Full Text] [Related]
15. Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Eur J Pharm Sci; 2017 Jun; 104():424-433. PubMed ID: 28455002
[TBL] [Abstract][Full Text] [Related]
16. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional analysis of doxorubicin-induced cytotoxicity and resistance in human hepatocellular carcinoma cell lines.
Wang J; Chan JY; Fong CC; Tzang CH; Fung KP; Yang M
Liver Int; 2009 Oct; 29(9):1338-47. PubMed ID: 19627484
[TBL] [Abstract][Full Text] [Related]
18. Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression.
Blaheta RA; Daher FH; Michaelis M; Hasenberg C; Weich EM; Jonas D; Kotchetkov R; Doerr HW; Cinatl J
BMC Cancer; 2006 Dec; 6():294. PubMed ID: 17181871
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment with doxorubicin and microRNA-21 inhibitor synergistically augments anticancer activity through upregulation of tumor suppressing genes.
Zhang S; Han L; Wei J; Shi Z; Pu P; Zhang J; Yuan X; Kang C
Int J Oncol; 2015 Apr; 46(4):1589-600. PubMed ID: 25625875
[TBL] [Abstract][Full Text] [Related]
20. Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma.
Godel M; Morena D; Ananthanarayanan P; Buondonno I; Ferrero G; Hattinger CM; Di Nicolantonio F; Serra M; Taulli R; Cordero F; Riganti C; Kopecka J
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
